中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.021 seconds)

    METHODS AND SYSTEMS FOR INHIBITING FOREIGN-BODY RESPONSES IN DIABETIC PATIENTS
    21.
    发明申请
    METHODS AND SYSTEMS FOR INHIBITING FOREIGN-BODY RESPONSES IN DIABETIC PATIENTS 审中-公开
    抑制糖尿病患者身体反应的方法和系统

    公开(公告)号：US20150112302A1

    公开(公告)日：2015-04-23

    申请号：US14512788

    申请日：2014-10-13

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Sarnath Chattaraj ,  Kiem H. Dang ,  Hsi Chung Fusselman ,  Poonam S. Gulati ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61K31/727 ,  A61L29/16 ,  A61L29/08 ,  A61M5/142 ,  A61K38/28

    Abstract: Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

    Abstract translation: 提供了用于减少糖尿病患者的异物免疫应答的方法和装置，包括输注部位损失和/或闭塞。 这种异物反应与治疗需要皮下植入异物如插管或导管的糖尿病患者的治疗相关联。 在本发明的某些实施方案中，在套管/导管插入部位向患者施用反应抑制剂，由此有助于将胰岛素递送至糖尿病患者并减轻一段时间的部位损失和/或闭塞。

    MEDICATION INFUSION COMPONENTS AND SYSTEMS
    22.
    发明申请
    MEDICATION INFUSION COMPONENTS AND SYSTEMS 有权

    公开(公告)号：US20250108150A1

    公开(公告)日：2025-04-03

    申请号：US18981099

    申请日：2024-12-13

    Applicant: MEDTRONIC MINIMED, INC.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    Medication infusion components and systems
    23.
    发明授权
    Medication infusion components and systems 有权

    公开(公告)号：US12201752B2

    公开(公告)日：2025-01-21

    申请号：US17499612

    申请日：2021-10-12

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    MEDICATION INFUSION COMPONENTS AND SYSTEMS
    25.
    发明申请
    MEDICATION INFUSION COMPONENTS AND SYSTEMS 有权

    公开(公告)号：US20220409777A1

    公开(公告)日：2022-12-29

    申请号：US17823388

    申请日：2022-08-30

    Applicant: MEDTRONIC MINIMED, INC.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61L29/14 ,  A61K38/28 ,  A61K31/727 ,  A61L29/04 ,  A61M5/142 ,  A61M5/38 ,  A61K9/00 ,  A61M39/10 ,  A61M39/16

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    IRREMOVABLE BUCKLING-RESISTANT FLEXIBLE CANNULA AND PROCESS
    26.
    发明申请
    IRREMOVABLE BUCKLING-RESISTANT FLEXIBLE CANNULA AND PROCESS 有权

    公开(公告)号：US20220401644A1

    公开(公告)日：2022-12-22

    申请号：US17352154

    申请日：2021-06-18

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Davy Tong ,  Kiem H. Dang ,  Hsi C. Fusselman ,  Sarnath Chattaraj ,  Thomas P. Miller

    IPC: A61M5/142 ,  A61M5/162 ,  A61M5/172

    Abstract: A cannula includes a tubular body having an axial dimension through which a flow channel extends. The tubular body has a first end for insertion into a subject, and a second end configured to be held within a base of a medical device. The tubular body has a first length portion extending along the axial dimension from the first end toward the second end. A second length portion extends along the axial dimension from the first length portion toward the second end, and has an outer dimension that flares outward to be larger than the outer dimension of the first length portion. The second length portion also has a tubing wall thickness that is greater than the tubing wall thickness of the first length portion.

    MEDICATION INFUSION COMPONENTS AND SYSTEMS
    27.
    发明申请
    MEDICATION INFUSION COMPONENTS AND SYSTEMS 有权

    公开(公告)号：US20220031941A1

    公开(公告)日：2022-02-03

    申请号：US17499612

    申请日：2021-10-12

    Applicant: Medtronic MiniMed, Inc.

    Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

    IPC: A61M5/168 ,  A61M5/142 ,  A61M5/162

    Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

    SET CONNECTOR SYSTEMS FOR VENTING A FLUID RESERVOIR
    28.
    发明申请
    SET CONNECTOR SYSTEMS FOR VENTING A FLUID RESERVOIR 审中-公开

    公开(公告)号：US20200164159A1

    公开(公告)日：2020-05-28

    申请号：US16776040

    申请日：2020-01-29

    Applicant: MEDTRONIC MINIMED, INC.

    Inventor： Sarnath Chattaraj ,  Kiem H. Dang ,  Poonam S. Gulati

    IPC: A61M5/36 ,  A61M5/142 ,  A61M39/10 ,  A61M5/168 ,  A61M39/24

    Abstract: A fluid infusion device includes a housing having a reservoir chamber that receives a fluid reservoir. The fluid reservoir has a first end and a second end. The fluid infusion device includes a connector system having a first body section coupled to a second body section. The first body section defines a bore in communication with a chamber and a counterbore of the second body section to define a fluid flow path. The chamber of the second body section is in fluid communication with a vent subsystem defined through the second body section. The vent subsystem terminates in an outlet, and the vent subsystem is to direct gas in the fluid flow path through the second body section to the outlet. The fluid infusion device includes at least one ring disposed within the reservoir chamber that cooperates with the connector system to securely couple the connector system to the housing.

Patent Agency Ranking